Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX), a global leader in 3D-printed biomimetic and bioresorbable implants, has entered a multi-year exclusive agreement with Majeton to commercialise its dental, orthodontic, and maxillofacial products across China, Hong Kong, and Macau.
Valued at over 12 million Chinese yuan, the deal includes upfront and milestone payments, with additional revenue expected from ongoing product supply, reflecting strong confidence in the regional market potential.
Majeton, a Southeast Asian sales, marketing, and distribution specialist backed by Hong Kong-listed Essex Bio-Technology, brings extensive expertise and a proven track record, with its products currently available in more than 13,500 hospitals and a 2024 turnover of HK$1.67 billion.